loading
Unicycive Therapeutics Inc stock is traded at $0.4864, with a volume of 924.33K. It is down -0.81% in the last 24 hours and up +27.37% over the past month. Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
See More
Previous Close:
$0.4799
Open:
$0.47
24h Volume:
924.33K
Relative Volume:
0.42
Market Cap:
$43.41M
Revenue:
-
Net Income/Loss:
$-30.54M
P/E Ratio:
-0.2457
EPS:
-1.98
Net Cash Flow:
$-18.30M
1W Performance:
-1.22%
1M Performance:
+27.37%
6M Performance:
-57.50%
1Y Performance:
-20.53%
1-Day Range:
Value
$0.451
$0.4864
1-Week Range:
Value
$0.451
$0.549
52-Week Range:
Value
$0.202
$1.818

Unicycive Therapeutics Inc Stock (UNCY) Company Profile

Name
Name
Unicycive Therapeutics Inc
Name
Phone
650-384-0642
Name
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Name
Employee
14
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
UNCY's Discussions on Twitter

Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-04-24 Initiated Piper Sandler Overweight

Unicycive Therapeutics Inc Stock (UNCY) Latest News

pulisher
Oct 29, 2024

Thinking about buying stock in Beyondspring, LAVA Therapeutics, - GuruFocus.com

Oct 29, 2024
pulisher
Oct 28, 2024

Unicycive Therapeutics Delivers Multiple Poster - GlobeNewswire

Oct 28, 2024
pulisher
Oct 28, 2024

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 - StockTitan

Oct 28, 2024
pulisher
Oct 16, 2024

Unicycive Therapeutics to Participate in a Fireside Chat at - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024 - StockTitan

Oct 16, 2024
pulisher
Oct 16, 2024

This trade activity should not be overlooked: Unicycive Therapeutics Inc (UNCY) - SETE News

Oct 16, 2024
pulisher
Oct 16, 2024

Unicycive Therapeutics, Inc. (NASDAQ:UNCY): Is Breakeven Near? - Simply Wall St

Oct 16, 2024
pulisher
Oct 15, 2024

A year in review: Unicycive Therapeutics Inc (UNCY)’s performance in the last year - US Post News

Oct 15, 2024
pulisher
Oct 14, 2024

Unicycive to present kidney disease therapies at ASN Kidney Week - Investing.com

Oct 14, 2024
pulisher
Oct 14, 2024

Unicycive Therapeutics Inc’s Market Journey: Closing Strong at 0.37, Up 3.12 - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Unicycive to present kidney disease therapies at ASN Kidney Week By Investing.com - Investing.com South Africa

Oct 14, 2024
pulisher
Oct 14, 2024

UNCYUnicycive Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 14, 2024
pulisher
Oct 14, 2024

Unicycive Therapeutics Announces Late-Breaker Poster - GlobeNewswire

Oct 14, 2024
pulisher
Oct 14, 2024

Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024 - Yahoo Finance

Oct 14, 2024
pulisher
Oct 12, 2024

Unicycive Therapeutics (UNCY) Price Target Increased by 21.14% to 5.41 - MSN

Oct 12, 2024
pulisher
Oct 11, 2024

Octagon Capital Advisors LP Acquires New Stake in Unicycive Therapeutics Inc - Yahoo Finance

Oct 11, 2024
pulisher
Oct 11, 2024

Octagon Capital Advisors LP Acquires New Stake in Unicycive Ther - GuruFocus.com

Oct 11, 2024
pulisher
Oct 10, 2024

H.C. Wainwright & Co. Shares Buy Rating on Biotech Co. - Streetwise Reports

Oct 10, 2024
pulisher
Oct 09, 2024

Unicycive reports successful phase 1 kidney drug trial - Investing.com

Oct 09, 2024
pulisher
Oct 09, 2024

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers - The Manila Times

Oct 09, 2024
pulisher
Oct 09, 2024

Unicycive reports successful phase 1 kidney drug trial By Investing.com - Investing.com UK

Oct 09, 2024
pulisher
Oct 08, 2024

Unicycive Therapeutics Inc (UNCY) is looking forward to a strong quarter - SETE News

Oct 08, 2024
pulisher
Oct 07, 2024

UNCY’s earnings forecast for the current quarter - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Ratio Analysis: Unpacking Unicycive Therapeutics Inc (UNCY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 07, 2024
pulisher
Oct 02, 2024

Unicycive Therapeutics Inc: Weathering Stock Market Storms with 35.62M Market Cap - The InvestChronicle

Oct 02, 2024
pulisher
Oct 01, 2024

Get in on Unicycive Therapeutics Inc’s (UNCY) buy-in window today! - SETE News

Oct 01, 2024
pulisher
Sep 30, 2024

Unicycive Therapeutics' SWOT analysis: stock potential in kidney disease market - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Was anything positive for Unicycive Therapeutics Inc (UNCY) stock last session? - US Post News

Sep 30, 2024
pulisher
Sep 25, 2024

What is Unicycive Therapeutics Inc (UNCY) Stock Return on Shareholders’ Capital? - SETE News

Sep 25, 2024
pulisher
Sep 25, 2024

Market Recap Check: Unicycive Therapeutics Inc (UNCY)’s Positive Finish at 0.44, Up/Down 2.82 - The Dwinnex

Sep 25, 2024
pulisher
Sep 24, 2024

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - ForexTV.com

Sep 24, 2024
pulisher
Sep 24, 2024

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor - EIN News

Sep 24, 2024
pulisher
Sep 23, 2024

Unicycive Therapeutics Inc (UNCY) deserves closer scrutiny - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Unicycive Therapeutics (NASDAQ:UNCY) and Aprea Therapeutics (NASDAQ:APRE) Head to Head Comparison - Defense World

Sep 23, 2024
pulisher
Sep 19, 2024

Take off with Unicycive Therapeutics Inc (UNCY): Get ready for trading - SETE News

Sep 19, 2024
pulisher
Sep 18, 2024

Examining Unicycive Therapeutics Inc (UNCY) more closely is necessary - US Post News

Sep 18, 2024
pulisher
Sep 18, 2024

Three Central African countries commit to global eradication of Guinea-worm disease - WHO | Regional Office for Africa

Sep 18, 2024
pulisher
Sep 17, 2024

Upward Trajectory: Unicycive Therapeutics Inc (UNCY) Posts a Slidee, Closing at 0.38 - The Dwinnex

Sep 17, 2024
pulisher
Sep 16, 2024

Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024 - StockTitan

Sep 16, 2024
pulisher
Sep 15, 2024

Uxin finds new friend on difficult road to profitability - Bamboo Works

Sep 15, 2024
pulisher
Sep 14, 2024

ICMR partners with industry leaders for groundbreaking First-in-Human Phase-1 clinical trials - ETHealthWorld

Sep 14, 2024
pulisher
Sep 11, 2024

Views of Wall Street’s Leading Experts on Unicycive Therapeutics Inc - SETE News

Sep 11, 2024
pulisher
Sep 11, 2024

Unicycive Therapeutics Inc’s Market Journey: Closing Strong at 0.39, Up 5.51 - The Dwinnex

Sep 11, 2024
pulisher
Sep 10, 2024

Unicycive Therapeutics Inc (UNCY) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle

Sep 10, 2024
pulisher
Sep 09, 2024

Unicycive Therapeutics Inc’s results are impressive - US Post News

Sep 09, 2024
pulisher
Sep 06, 2024

Unicycive stock remains Speculative Buy-rated by Benchmark; optimistic on FDA submission - Investing.com

Sep 06, 2024
pulisher
Sep 05, 2024

Unicycive Therapeutics Inc (UNCY) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle

Sep 05, 2024
pulisher
Sep 05, 2024

There is no way Unicycive Therapeutics Inc (UNCY) can keep these numbers up - SETE News

Sep 05, 2024
pulisher
Sep 05, 2024

Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Bakersfield Californian

Sep 05, 2024
pulisher
Sep 05, 2024

Shilpa Medicare announces submission of NDA for Oxylanthanum Carbonate to USFDA by Unicycive Therapeutics - Medical Dialogues

Sep 05, 2024
pulisher
Sep 04, 2024

Unicycive retains Buy rating, stock target post-NDA submission By Investing.com - Investing.com Canada

Sep 04, 2024

Unicycive Therapeutics Inc Stock (UNCY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.30
price up icon 1.75%
$75.59
price down icon 0.20%
$374.10
price down icon 0.29%
$52.67
price down icon 0.85%
$207.67
price up icon 0.20%
$108.59
price up icon 0.02%
Cap:     |  Volume (24h):